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Background: Streptococcus suis serotype 2 (S. suis 2) has evolved efficient mechanisms to cause streptococcal toxic
shock syndrome (STSS), which is a new emerging infectious disease linked to S. suis. We have previously reported
that a type IV secretion system (T4SS) harbored by the specific 89K pathogenicity island (PAI) of S. suis 2 contributes
to the development of STSS and mediates horizontal transfer of 89K. However, the 89K T4SS machinery assembly
in vivo and in vitro is poorly understood, and the component acting directly to digest the bacterial cell wall needs
to be identified.
Results: The virB1-89K gene product encoded in the 89K PAI is the only one that shows similarity to the
Agrobacterium VirB1 component and contains a conserved CHAP domain that may function in peptidoglycan
hydrolysis, which makes it a plausible candidate acting as a hydrolase against the peptidoglycan cell wall to allow
the assembly of the T4SS apparatus. In the current study, the CHAP domain of VirB1-89K from S. suis 89K PAI was
cloned and over-expressed in Escherichia coli, and its peptidoglycan-degrading activity in vitro was determined. The
results indicated that the VirB1-89K CHAP domain can degrade the peptidoglycan layer of bacteria. Deletion of
virB1-89K reduces significantly, but does not abolish, the virulence of S. suis in a mouse model.
Conclusions: The experimental results presented here suggested that VirB1-89K facilitates the assembly of 89K T4SS
apparatus by catalyzing the degradation of the peptidoglycan cell wall, thus contributing to the pathogenesis of
S. suis 2 infection.
Keywords: Streptococcus suis serotype 2, Streptococcal toxic shock syndrome, Type IV secretion system,
Pathogenicity island, Assembly, Peptidoglycan hydrolaseBackground
Streptococcus suis serotype 2 (S. suis 2), an important
zoonotic pathogen worldwide, has evolved to be a serious
problem over the past two decades [1-3]. It was reported
that S. suis 2 only causes sporadic cases of human infection
with a mortality of less than 10% [4,5]. However, it emerged
as the leading cause of two large-scale outbreaks of severe
epidemics in China in 1998 and 2005, respectively [6]. The
unusual outbreaks affected over 200 individuals and killed
52 of them [7,8]. Besides its large size and the associated* Correspondence: hufuquan2009@aliyun.com; sotx7080@163.com
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unless otherwise stated.high mortality rate, these two outbreaks are unique in
that a large proportion of patients were victim to
streptococcal toxic shock syndrome (STSS) [7]. Before
that, STSS has been limited to disease caused by the
group A streptococcus [9], S. suis (nongroup A) has
not previously been linked to STSS.
To get insight into the high virulence of the S. suis
isolates emerged in China, we previously decoded
the whole genomic sequence of two epidemic strains
(98HAH12 and 05ZYH33) isolated from the 1998 and
2005 Chinese outbreaks respectively, and identified a
pathogenicity island (PAI) designated 89K that is specific
for Chinese outbreak isolates [10,11]. Subsequently, we
provided genetic evidence showing that an 89K-borne typeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for horizontal transfer of 89K and secretion of some
unknown pathogenic effectors that are responsible for
STSS caused by the highly virulent S. suis 2 strains [12,13].
However, the 89K T4SS assembly process in vivo and
in vitro remains largely unknown.
There has long been a general lack of knowledge of
T4SS functions and cellular localization in gram-positive
bacteria [14]. It has been suggested that the assembly
processes must be similar to or even simpler than those
in gram-negative bacteria [15,16]. In the well-characterized
model for the Agrobacterium tumefaciens VirB/D T4SS, the
VirB1 component functions as a lytic transglycosylase that
can digest the peptidoglycan layer of cell wall, thus fa-
cilitating the assembly of envelope-spanning protein
complex of T4SS under temporal and spatial control
[17,18]. Among the single operon composed of 15
genes that encodes the functional T4SS in S. suis 89K
PAI, only the virB1-89K gene product shows similarity
to the Agrobacterium VirB1 component and contains a
conserved cysteine, histidine-dependent amidohydrolases/
peptidases (CHAP) domain that may function in peptido-
glycan hydrolysis [19]. We once proposed that VirB1-89K
should function to punch holes in the peptidoglycan
cell wall to allow the assembly of the T4SS apparatus
[12]. However, we did not provide direct evidence to
support this hypothesis.
In the present study, therefore, we expressed and purified
the CHAP domain of VirB1-89K in Escherichia coli, and
tested its putative peptidoglycan hydrolysis activity in vitro.
Furthermore, an isogenic knockout mutant of virB1-89K
and its complementary strain were used in a mouse infec-
tion model to assess the contribution of VirB1-89K to the
virulence of S. suis outbreak strain. The experimental
results indicated that VirB1-89K facilitates the assembly
of 89K T4SS apparatus by catalyzing the degradation of the
peptidoglycan cell wall, thus contributing to the pathogen-
esis of T4SS in the S. suis.
Results
Characterization of the CHAP domain of VirB1-89K
On the negative strand of the 89K PAI in the genome of
S. suis 05ZYH33 (GenBank accession number NC_009442),
peptide encoded by 05SSU0968 shows 18% similarity to
the VirB1 component of the Agrobacterium T4SS and was
designated VirB1-89K. Based on sequence analysis, VirB1-
89K was predicted to contain a C-terminal CHAP domain
(located between the amino acids 796 and 926) and an
N-terminal transmembrane domain, but lacks a signal
sequence. The CHAP domain is broadly found in proteins
from bacteria, phages, archaea, and eukaryotes of the
Trypanosomidae family [19,20]. It has been proposed
that the CHAP domain may function mainly in pep-
tidoglycan hydrolysis [19]. The phylogenetic analysis ofVirB1-89K and its homologous proteins showed that
VirB1-89K and N-acetylmuramoyl-L-alanine amidase
probably originate from the same ancestor (Figure 1A).
Tertiary structure prediction showed that the CHAP
domain of VirB1-89K belongs to the α + β structural class,
with the N-terminal half containing 3 predicted α-helices
and the C-terminal half composed of 6 predicted β-strands
(Figure 1B). Protein tertiary structure modeling revealed
that this CHAP domain contains an putative active cen-
ter composed of a conserved cysteine and a histidine
(Figure 1C), these two invariant residues form the main
part of the active site of CHAP domain containing pro-
teins [19,21,22]. These results together with the above
phylogeny analysis suggested that VirB1-89K may be
an N-acetylmuramyl-L-alanine amidase.
Expression and purification of the CHAP domain of VirB1-89K
To figure out the function of VirB1-89K during the as-
sembly of 89K T4SS apparatus, a 411 bp DNA fragment
containing the CHAP domain of VirB1-89K was cloned
and over-expressed in E. coli as a C-terminally His6-tagged
protein. The protein of interest was designated VirB1-
89KCHAP. We found VirB1-89KCHAP was efficiently
expressed after induction at 16°C (Figure 2A). The mo-
lecular mass of the expressed recombinant protein agreed
well with a predicted size of 15.4 kDa. Although a majority
of the VirB1-89KCHAP protein was present in the inclu-
sion body fractions of crude cell lysates, sufficient soluble
material was produced to recover useful amounts of active
protein. Highly purified protein (>95% homogeneity) was
prepared by Ni+ affinity chromatography and gel filtration
(Figure 2B). N-terminal sequencing results confirmed that
the produced protein was indeed the CHAP domain of
VirB1-89K.
Lytic activity and biochemical characterization of
VirB1-89KCHAP
To determine the muramidase activity of the purified
VirB1-89KCHAP protein, peptidoglycan hydrolase activity
was analyzed by using zymography with S. suis peptidogly-
can as substrate. After SDS-PAGE, the positive control hen
egg white lysozyme, the negative control BSA protein, and
the VirB1-89KCHAP protein could be seen after staining
with Coomassie blue (Figure 3A). The gel was then stained
with methylene blue to detect peptidoglycan hydrolase
activity as a clear zone against a dark blue background.
We noticed that VirB1-89KCHAP exhibited apparent
enzyme activity as the positive control did, while the nega-
tive control BSA did not (Figure 3B). These zymography
data suggested that the VirB1-89KCHAP protein could
solubilize the cell wall of S. suis 2.
In another set of experiments, the bacteriostatic activity
of VirB1-89KCHAP was determined with slip diffusion
method to confirm its peptidoglycan hydrolase activity.
Figure 1 Sequence analysis of VirB1-89K. (A) Phylogenetic analysis of VirB1-89K. Sequence alignment and phylogenetic analysis of VirB1-89K
homologs were performed using MEGA 5.1 software. Values at nodes indicate bootstrap values for 500 replicates. (B) Analysis of the tertiary
structure of the CHAP domain of VirB1-89K by using the online server SWISS-MODEL. (C) Visualization of the surface active site of the CHAP
domain by using PyMOLviewer, showing the cysteine residue in green and histidine in red.
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hen egg white lysozyme could suppress the growth of
S. suis 2, while the BSA control could not (Figure 3C).
To reveal the basic biological characteristics of VirB1-
89KCHAP, we examined the optimum reaction condition
of VirB1-89KCHAP by using Micrococcus lysodeikticus
cells as substrate. Results showed that on increasing the
pH, peptidoglycan hydrolase activity of VirB1-89KCHAP
increases and reaches maximum at pH 8.0 (Figure 4A).
When the pH exceeds 9.0, the relative activity decreased
sharply. VirB1-89KCHAP functions best at an optimal
temperature of 40°C. The enzyme activity rapidly declinedFigure 2 Over-expression and purification of VirB1-89KCHAP. (A) SDS-P
E. coli. Lanes: 1, total crude extracts after IPTG induction; 2, sonicated supernat
noninduced cells. Protein size marker is indicated on the left. (B) The purified Viat temperatures above 50°C and only 25% of the maximal
activity was measured at 60°C (Figure 4B). From the thermal
stability data, the relative activity is higher at 30°C than at
40°C, suggesting that pre-incubation of VirB1-89KCHAP at
30°C causes lower decay in relative activity compared to the
enzyme pre-incubated at 40°C (Figure 4C). With increasing
temperature, pre-incubation of VirB1-89KCHAP caused in-
creasing decay in the relative activity of the enzyme.
Role of VirB1-89K in bacterial virulence
To assess the role of VirB1-89K in bacterial virulence,
an isogenic knockout mutant of virB1-89K (ΔvirB1-89K)AGE analysis (12%) of the interest VirB1-89KCHAP protein expressed in
ant of induced cells; 3, sonicated sediment of induced cells; 4,
rB1-89KCHAP protein after Ni+ affinity chromatography and gel filtration.
Figure 3 Lytic activity detection of VirB1-89KCHAP. Zymography analysis of peptidoglycan hydrolase activity of VirB1-89KCHAP. The gel was
stained with Coomassie blue (A) and then overstained with Methylene blue (B). (C) Bacteriostatic activity of VirB1-89KCHAP. Proteins used: 1, hen
egg white lysozyme; 2, BSA; 3, VirB1-89KCHAP.
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strain CΔvirB1-89K were subjected to experimental infec-
tion of mice [12]. We found that group of mice infected
with the wild-type strain 05ZYH33 developed obvious
clinical signs of S. suis infection, including rough hair coat,
weight loss, depression, shivering, and suppuration of the
eyes. There were no survivors at 12 hours post-infection
(Figure 5). However, mice in the ΔvirB1-89K mutant
group were all alive at 12 hours post-infection and had
a survival rate of 70% at the experimental end point of
7 days. When mice were challenged with the complemen-
ted strain, CΔvirB1-89K, data similar to those obtained
with the wild-type strain were observed. In the THYcontrol
group, all mice survived without any disease symptoms
during the entire experiment. These results strongly in-
dicated that VirB1-89K is involved in the pathogenesis
of Chinese epidemic S. suis 2 strains.
Discussion
T4SSs are versatile devices that are found in many bac-
terial pathogens and secrete a wide variety of substrates,
from single protein to protein-protein and protein-DNA
complexes. They are generally composed of a dozenFigure 4 Dynamic changes in lytic activity of VirB1-89KCHAP at differ
activity of VirB1-89KCHAP. (B) The effect of temperature on enzyme activity
Results shown are representative of three independent experiments.components that are organized into ATP-powered protein
complexes spanning the entire cell envelope. In this macro-
molecular secretion apparatus, the VirB1 component can
lysis cell wall peptidoglycan of the bacteria to facilitate the
assembly of T4SS [23]. Many VirB1 components in gram-
negative bacteria are lytic transglycosylases that can cleave
the β-1,4 glycosidic bond between N-acetylglucosamine
(GlcNAc) and N-acetylmuramic acid (MurNAc), with
the concomitant formation of a β-1,6-anhydromuramoyl
product [24-27]. In some cases, the VirB1 orthologs can
be N-acetylmuramoyl-L-alanine amidases that cleave the
link between N-acetylmuramoyl residues and L-amino acid
residues in certain cell wall glycopeptides [28]. In this study,
sequence alignment and phylogenetic analysis showed that
the VirB1-89K protein may be an N-acetylmuramoyl-L-
alanine amidase.
To explore the potential role of VirB1-89K in S. suis, we
engineered the CHAP domain of VirB1-89K for heterol-
ogous expression for three reasons: i) the total length of
VirB1-89K is as long as 933 amino acids located within a
transmembrane region, suggesting it may be difficult to
express and purify the full-length VirB1-89K protein; ii)
the main function of a certain protein depends on itsent pH values or temperatures. (A) The effect of pH on enzyme
of VirB1-89KCHAP. (C) Thermostability of the VirB1-89KCHAP protein.
Figure 5 Survival curves of mice infected with S. suis 05ZYH33,
the ΔvirB1-89K mutant, the complemented strain CΔvirB1-89K,
and the THY medium. Mice (10 per group) were inoculated
intraperitoneally with 108 CFU bacteria. Results shown are
representative of three independent experiments.
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of the functional domain may be higher than the full-length
protein [29]. By using S. suis peptidoglycan as the substrate
for zymogram analysis, we visually detected the mura-
midase activity of the purified VirB1-89KCHAP protein.
In addition, the bacteriostatic activity of VirB1-89KCHAP
was also observed with slip diffusion method. These data
confirmed the peptidoglycan hydrolase activity of VirB1-
89KCHAP, indicating the VirB1-89K component may play
a crucial role in piercing the peptidoglycan layer in the
cell wall of S. suis 2 during the assembly of the T4SS
transenvelope transporter complex.
Recently, we reported that the T4SS encoded within
the 89K PAI not only contributes to the development of
STSS [13], but also mediates the conjugal transfer of 89K
itself [12]. The transfer frequency of 89K was reduced
approximately 6-fold in a virB1-89K deletion mutant
(ΔvirB1-89K) [12]. In this study, we found that the viru-
lence of the ΔvirB1-89K mutant was reduced to 30% com-
pared to the wild-type level. A similar phenomenon had
been reported that the virB1 defection in A. tumefaciens
can cause a marked reduction of virulence to 1%-10% of
the wild-type level [25,30]. These results indicated that the
VirB1 orthologs are important for a functional T4SS, their
absence would disturb the proper assembly of the transen-
velope apparatus, thus leading to unsuccessful release of
the T4SS substrates.
Recent studies suggested that Cagγ, the Helicobacter
pylori homologue of VirB1, is essential for the CagA
effector translocation [31]. However, little is known
about the effectors delivered by the S. suis T4SS that are
responsible for STSS. Work currently underway in our
laboratory seeks to determine these pathogenic effectors.Furthermore, our future research will focus on the differ-
ence in crystal structure between the VirB1 component in
gram-negative A. tumefaciens and its counterpart in gram-
positive S. suis, thus facilitating our understanding of the
assembly of the T4SS apparatus in gram-positive bacteria.
Conclusions
In summary, we characterized a functional peptidoglycan
hydrolase from T4SS in the 89K PAI of Chinese epidemic
S. suis 2. In the operon coding for the 89K T4SS, the
virB1-89K gene product is the only one that shows
similarity to the Agrobacterium VirB1 component and
contains a conserved CHAP domain. In this work, the
purified CHAP domain of VirB1-89K exhibited evident
peptidoglycan-degrading and bacteriostatic activity in vitro.
Inactivation of virB1-89K reduces significantly the virulence
of S. suis in a mouse infection model. The experimental
results indicated that VirB1-89K facilitates the assembly of
89K T4SS apparatus by breaking apart the peptidoglycan
cell wall, thus contributing to the horizontal transfer of 89K
and the pathogenesis of T4SS in S. suis infection.
Methods
Bacterial strains, plasmids, and growth conditions
The bacterial strains and plasmids used in this study are
listed in Table 1. S. suis strains were grown in Todd-Hewitt
broth (THB) supplemented with 2% yeast extract (THY).
E. coil and M. lysodeikticus strains were cultured in Luria-
Bertani (LB) medium at 37°C. Solid medium was prepared
by the addition of 1.5% agar. When necessary, antibiotics
were added at the following concentrations: spectinomycin,
100 μg/ml for both S. suis and E. coli; chloramphenicol,
5 μg/ml for S. suis and 10 μg/ml for E. coli; ampicillin,
100 μg/ml for E. coli.
Bioinformatics analysis and functional prediction of
VirB1-89K
Sequences were analyzed by using the DNAStar software
package. Sequence alignment was performed by using
BLAST at NCBI (http://www.ncbi.nlm.nih.gov/blast/).
The conserved domain of VirB1-89K was analyzed using
the Pfam online server (http://pfam.sanger.ac.uk/). The
presence and location of signal peptide was predicted by
SignalP 3.0 server (http://www.cbs.dtu.dk/services/SignalP/).
The tertiary structure of the conserved domain was
determined using SWISS-MODEL web server (http://
swissmodel.expasy.org/) and the PyMOL viewer software.
Phylogenetic analysis of VirB1-89K was conducted using
the MEGA version 5.1 program.
Cloning, expression, and purification of VirB1-89KCHAP
A 411 bp fragment encoding the CHAP domain of VirB1-
89K was amplified from S. suis 05ZYH33 genomic DNA
with the forward (5′-GAGACATATGGATTTTTTTGA
Table 1 Bacterial strains and plasmids used in this study
Strains/plasmids Relevant characteristics* Source/reference
Strains
S. suis
05ZYH33 A highly virulent strain isolated from a dead patient with STSS Lab collection
ΔvirB1-89K An isogenic virB1-89K mutant of strain 05ZYH33; Spcr [12]
CΔvirB1-89K Complemented strain of ΔvirB1-89K; Spcr; Cmr [12]
M. lysodeikticus
ATCC4698 Suitable for substrate for the assay of lysozyme Sigma-Aldrich
E. coli
DH5α Cloning host for maintaining the recombinant plasmids Lab collection
BL21(DE3) Expression host for exogenous protein production Lab collection
Plasmids
pMD19-T Cloning vector; Ampr TaKaRa
pET-21a(+) His-tag fusion expression vector; Ampr Novagen
pET21a-CHAP A recombinant vector with the background of pET-21a(+),
designed for expression of the CHAP domain of VirB1-89K; Ampr
This work
*Ampr, ampicillin resistant; Cmr, chloramphenicol resistant; Spcr, spectinomycin resistant.
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TTTCGTCGTATAAGCAAAAC-3′) primers carrying the
Nde I and Xho I restriction sites, respectively. The result-
ing PCR products were cloned into the appropriate sites
of the pET-21a(+) plasmid, creating the recombinant
expression vector pET21a-CHAP. A single colony of
E. coli BL21(DE3) containing pET21a-CHAP was inocu-
lated in LB medium and grew overnight, then diluted
1:100 into 2 L of LB medium and was grown at 37°C to an
OD600 of 0.6. Induce cells with IPTG to a final concentra-
tion of 1 mM and grow the cultures at 16°C for an add-
itional 10 hours. Cells were harvested by centrifugation at
6,000 rpm for 15 min, and the pellet was resuspended in
100 ml binding buffer (20 mM Na3PO4, 0.5 M NaCl,
pH 8.0), and then ultrasonic treatment was performed on
ice. The supernatant was collected by centrifugation, and
the elution buffer (20 mM Na3PO4, 0.5 M NaCl, 0.5 M
imidazole, pH 8.0) in accordance with 1:20 were added.
The protein of interest (VirB1-89KCHAP) was purified on
His GraviTrap column prepacked with Ni Sepharose 6
Fast Flow, then washed with binding buffer until the
absorbance reaches the baseline. The target protein
was eluted with elution buffer using a linear gradient.
The elution was checked by SDS-PAGE (12%) and fractions
containing the interest protein were further purified by gel
filtration chromatography using Superdex-75 column. Peak
elution fractions were analyzed by gel electrophoresis and
those containing pure protein were pooled and concen-
trated in an Amicon apparatus (Millipore) with a 10-kDa
molecular weight cutoff membrane, then stored in 0.1-ml
aliquots at −80°C. The protein concentration was deter-
mined by using the Pierce BCA protein assay kit.Determination of the lytic activity of VirB1-89KCHAP
To determine the peptidoglycan-degrading activity of
VirB1-89KCHAP, zymogram analysis was performed as
described previously [32,33]. Peptidoglycan isolated and
purified from S. suis 2 was added into 12% polyacrylamide
gels to a final concentration of 100 mg/ml [24,34]. After
electrophoresis, the gels were incubated at 37°C in renatur-
ation buffer (20 mM sodium phosphate buffer, 0.1% Trition
X-100, 10 mM MgCl2, pH 8.0) for 16 h, and then stained
with 1% methylene blue containing 0.1% KOH. The deion-
ized water was used for depolarization.
The bacteriostatic activity of VirB1-89KCHAP was
determined with slip-agar diffusion method [35]. A small
piece of filter paper loaded with purified VirB1-89KCHAP
was placed on a 1.5% agar plate inoculated with S. suis 2
cells, and then bacteriostatic rings of protein-sensitive slips
were generally observed after incubation and the diameters
of bacteriostatic rings were measured with a vernier caliper.
Hen egg white lysozyme and BSA were used as positive
and negative controls, respectively.
The effect of pH and temperature on the enzymatic
activity of VirB1-89KCHAP
The effect of pH and temperature on the enzymatic ac-
tivity of VirB1-89KCHAP was determined as previ-
ously described with minor modifications [31]. Purified
VirB1-89KCHAP protein was added to 200 μl the dried
cells of M. lysodeikticus as substrate. To determine the
optimal pH value, the enzyme activity was monitored
at 37°C with different pH values ranging from 3.0 to
11.0. The optimum temperature of the enzyme was
tested at the temperature ranging from 20°C to 70°C at
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the enzyme was pre-incubated at temperatures between
30°C and 90°C for 30 min, and the remaining activity was
determined under the optimum reaction conditions.
In vivo virulence studies
To determine whether the virB1-89K gene is necessary
for the virulence of the highly pathogenic S. suis 2,
experimental infection was performed as previously
described [36]. Randomized groups of 10 BALB/c mice
(4-week-old, female) were challenged intraperitoneally
with the wild-type, the isogenic knockout mutant of
virB1-89K (ΔvirB1-89K), and the complementary strain
CΔvirB1-89K, at a dose of 108 CFU (0.1 ml of each strain)
respectively. In parallel, another group of mice was injected
with the same volume of THY medium as a negative
control. Mice were monitored for clinical signs and survival
time for 7 days. All the experiments were approved by the
Laboratory Animal Welfare and Ethics Committee of the
Third Mililary Medical University.
Statistical analysis
Where appropriate, the data were analyzed using Student’s
t-test, and a value of P < 0.05 was considered significant.
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